0001104659-22-057509.txt : 20220509 0001104659-22-057509.hdr.sgml : 20220509 20220509161023 ACCESSION NUMBER: 0001104659-22-057509 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220509 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220509 DATE AS OF CHANGE: 20220509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cara Therapeutics, Inc. CENTRAL INDEX KEY: 0001346830 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36279 FILM NUMBER: 22905014 BUSINESS ADDRESS: STREET 1: 4 STAMFORD PLAZA STREET 2: 107 ELM STREET 9TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06902 BUSINESS PHONE: 203-406-3700 MAIL ADDRESS: STREET 1: 4 STAMFORD PLAZA STREET 2: 107 ELM STREET 9TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06902 FORMER COMPANY: FORMER CONFORMED NAME: Cara Therapeutics Inc DATE OF NAME CHANGE: 20051213 8-K 1 tm2214843d1_8k.htm FORM 8-K
0001346830 false 0001346830 2022-05-09 2022-05-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) May 9, 2022

  

CARA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-36279   75-3175693

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

         

4 Stamford Plaza

107 Elm Street, 9th Floor

Stamford, Connecticut

       06902
 (Address of principal executive offices)       (Zip Code)
         
Registrant's telephone number, including area code (203) 406-3700
         

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

  

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol Name of each exchange on which registered
Common Stock, par value $0.001 per share CARA The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨.

 

 

   

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On May 9, 2022, Cara Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2022. A copy of the press release is being furnished to the Securities and Exchange Commission as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 2.02.

 

The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any of the Company’s filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such a filing.

 

Item 9.01.Financial Statements and Exhibits.

 

(d)          Exhibits  

 

Exhibit No.   Description
     
99.1   Press Release dated May 9, 2022
104   Cover page interactive data file (formatted as Inline XBRL)

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

CARA THERAPEUTICS, INC. 

   
  By: /s/ Thomas Reilly
    Thomas Reilly
    Chief Financial Officer
    (Principal Financial and Accounting Officer)

 

Date: May 9, 2022

 

3 

 

 EX-99.1 2 tm2214843d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1 

 

 

 

Cara Therapeutics Reports First Quarter 2022 Financial Results

 

KORSUVA™ (difelikefalin) injection U.S. commercial launch began in April 2022 and is tracking to expectation

 

Kapruvia® (difelikefalin) approved by European Commission for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients, triggering $15M milestone payment to Cara

 

Top-line data from Phase 2 proof-of-concept trial of Oral KORSUVA (difelikefalin) in notalgia paresthetica expected in 2Q 2022

 

Oral KORSUVA (difelikefalin) Phase 3 pruritus programs in non-dialysis dependent advanced chronic kidney disease and atopic dermatitis underway

 

Conference call today at 4:30 p.m. ET

 

STAMFORD, Conn., May 9, 2022 – Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the first quarter ended March 31, 2022.

 

“We kicked off 2022 with substantial progress and execution of our mission to establish Cara Therapeutics as the leader in the treatment of chronic pruritus,” said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics. “In collaboration with our commercial partner Vifor Pharma, KORSUVA™ (difelikefalin) injection has launched in the U.S. and early performance indicators are in line with our expectations. Specifically, KORSUVA injection is available to be ordered by dialysis clinics nationwide, nephrologists are aware of KORSUVA injection and are ready and starting to prescribe, and patient outreach is expanding through additional channels. In April, the European Commission and the UK Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorization to Kapruvia® (difelikefalin), making it the first approved therapy in Europe for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients.”

 

Mr. Posner continued, “We’re also pleased with the progress across our Oral KORSUVA (difelikefalin) programs in multiple pruritus indications, which we believe represent significant market opportunities and tremendous patient needs. As discussed during our R&D Day, we initiated Phase 3 programs for pruritus associated with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. During this second quarter, we look forward to reporting top-line data from our Phase 2 proof-of-concept trial in notalgia paresthetica, in which we’re looking for an efficacy signal. Lastly, we expect to have top-line data from our Phase 2 trial in primary biliary cholangitis in the second half of 2022. Our solid financial footing, first-of-its-kind commercial product in KORSUVA injection and Oral KORSUVA (difelikefalin) pipeline put us on the path to create significant value and future growth.”

 

 

 

 

First Quarter and Recent Developments:

 

KORSUVA Injection: Chronic Kidney Disease-Associated Pruritus: Hemodialysis

 

In April 2022, the Company and its commercial partner, Vifor Pharma, commercially launched KORSUVA (difelikefalin) injection in the U.S. for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Transitional Drug Add-On Payment Adjustment (TDAPA) and the J-code for KORSUVA injection were effective as of April 1, 2022. Vifor’s field force of roughly 100 representatives has shifted its promotional efforts from patient identification to promoting KORSUVA injection. Furthermore, Vifor has shipped initial stocking orders of KORSUVA injection to the distribution channel.

 

In April 2022, the European Commission granted marketing authorization to Kapruvia® (difelikefalin) for the treatment of moderate-to-severe pruritus associated with CKD in adult hemodialysis patients. The marketing authorization approves Kapruvia for use in all member states of the European Union plus Iceland, Liechtenstein and Norway. Also in April, the Medicines and Healthcare products Regulatory Agency (MHRA) granted a UK Marketing Authorization. The first market launches in Europe are expected in the second half of 2022. This EU approval triggered a $15 million milestone payment to Cara.

 

Oral KORSUVA (difelikefalin): Pruritus Associated with Non-Dialysis Dependent Advanced Chronic Kidney Disease

 

The Company initiated a Phase 3 program of Oral KORSUVA (difelikefalin) in patients with advanced CKD stages 4 or 5 with moderate-to-severe pruritus who are not on dialysis. The Phase 3 program is comprised of two identical 12-week, double-blind, placebo-controlled studies, known as KICK 1 and KICK 2. Each study is expected to enroll approximately 400 patients who will be randomized 1:1 to either Oral KORSUVA (difelikefalin) 1 mg once daily or placebo. The primary endpoint is the proportion of patients with ≥4-point improvement at Week 12 from baseline in the Worst Itch Numeric Rating Scale (WI-NRS) score. The Company expects to report top-line results in the second half of 2024.

 

After the initial 12-week treatment period, patients are allowed to enter the safety extension. Patients will be re-randomized to either Oral KORSUVA (difelikefalin) or placebo for up to 52 weeks.

 

Oral KORSUVA (difelikefalin): Atopic Dermatitis

 

The Company initiated a Phase 3 program for Oral KORSUVA (difelikefalin) as an adjunctive therapy to topical corticosteroids (TCS) in atopic dermatitis patients with moderate-to-severe pruritus. The program is comprised of two studies, known as KIND 1 and KIND 2. Both studies are double-blind, controlled, 12-week studies with patients allowed to roll over to 52-week open-label safety extensions. KIND 1 is composed of two parts, Part A and Part B. Part A is expected to include 280 patients who will be randomized equally to four arms – Oral KORSUVA (difelikefalin) 0.25 mg twice daily + TCS, Oral KORSVUA (difelikefalin) 0.5 mg twice daily + TCS, placebo twice daily + TCS, and placebo twice daily + vehicle. At the end of the 12-week treatment period in Part A, the Company expects to have an internal data readout in the second half of 2023, to inform the dose and sample size to initiate Part B and KIND 2.

 

2

 

 

Oral KORSUVA (difelikefalin): Notalgia Paresthetica

 

The Company is evaluating the efficacy and safety of Oral KORSUVA (difelikefalin) for moderate-to-severe pruritus in approximately 120 patients with notalgia paresthetica (NP) in a Phase 2 proof-of-concept trial. In this multicenter, randomized, double-blind, placebo-controlled 8-week trial, patients are randomized to receive Oral KORSUVA (difelikefalin) 2.0 mg twice daily versus placebo for 8 weeks, followed by a 4-week active extension period. The primary efficacy endpoint is the change from baseline in the weekly mean of the daily 24-hour WI-NRS score at week 8 of the treatment period. Secondary endpoints include itch-related quality of life scores and sleep assessments. The Company expects to report top-line results from this trial in the second quarter of 2022.

 

Oral KORSUVA (difelikefalin): Chronic Liver Disease-Associated Pruritus: Primary Biliary Cholangitis

 

The Company is currently conducting a proof-of-concept Phase 2 clinical trial of Oral KORSUVA (difelikefalin) for the treatment of pruritus in patients with hepatic impairment due to primary biliary cholangitis (PBC). The trial is evaluating the safety and efficacy of Oral KORSUVA (difelikefalin) (1.0 mg tablet, twice daily) versus placebo for 16 weeks. The Company expects to report top-line data in the second half of 2022.

 

Upcoming Meeting Activities:

 

The Company expects to make presentations at the following upcoming conferences:

 

·BofA Securities 2022 Healthcare Conference, May 10-12
·H.C. Wainwright Global Investment Conference, May 23-26
·Jefferies Healthcare Conference, June 8-10

 

First Quarter 2022 Financial Results

 

Cash, cash equivalents and marketable securities at March 31, 2022 totaled $209.6 million compared to $236.8 million at December 31, 2021. The decrease in the balance primarily resulted from $25.5 million of cash used in operating activities.

 

3

 

 

For the first quarter of 2022, net loss was $27.7 million, or $(0.52) per basic and diluted share, compared to net loss of $23.3 million, or ($0.47) per basic and diluted share, for the same period in 2021.

 

Revenues: Total revenue was $4.8 million for the three months ended March 31, 2022, compared to $1.9 million during the same period of 2021. Revenue consisted of:

 

·$4.8 million of commercial supply revenue related to sales of KORSUVA injection to Vifor Pharma for the three months ended March 31, 2022. There was no commercial supply revenue for the same period in 2021.

 

·There was no license and milestone fees revenue or collaborative revenue for the three months ended March 31, 2022. $1.9 million of license and milestone fees revenue and collaborative revenue for the three months ended March 31, 2021 related to the milestone payment the Company earned from Maruishi Pharmaceutical Co. Ltd.’s (Maruishi) first initiation of a Phase 3 trial for uremic pruritus in Japan under the agreement with Maruishi.

 

Cost of Goods Sold (COGS): Through February 2022, the Company had not recorded any COGS related to its commercial supply revenue as all inventory costs were incurred prior to receipt of regulatory approval of KORSUVA injection and, accordingly, were expensed as incurred. In March 2022, the Company recorded commercial supply revenue of $2.5 million, with associated COGS of $2.1 million as these inventory costs were incurred subsequent to the receipt of regulatory approval of KORSUVA injection.

 

Research and Development (R&D) Expenses: R&D expenses were $21.3 million for the three months ended March 31, 2022 compared to $19.1 million in the same period of 2021. The higher R&D expenses in 2022 were principally due to increases in direct clinical trial costs and related consultant costs and payroll related costs, partially offset by a decrease in stock-based compensation expense.

 

General and Administrative (G&A) Expenses: G&A expenses were $9.3 million for the three months ended March 31, 2022 compared to $6.4 million in the same period of 2021. The higher G&A expenses in 2022 were principally due to increases in stock-based compensation expense, which included additional compensation expense relating to the modification of the Company’s former Chief Executive Officer’s equity awards in November 2021, as well as increases in consultants’ costs, legal fees, and payroll related costs.

 

Other Income, net: Other income, net was $0.2 million for the three months ended March 31, 2022 compared to $0.3 million in the same period of 2021. The decrease in other income, net was primarily due to an increase in net amortization expense of available-for-sale marketable securities and realized gains on sales of available-for-sale securities and property and equipment during the three months ended March 31, 2021, partially offset by an increase in interest income resulting from a higher yield on the Company’s portfolio of investments in the 2022 period.

 

4

 

 

Financial Guidance

 

Based on timing expectations and projected costs for current clinical development plans, Cara expects that its current unrestricted cash and cash equivalents and available-for-sale marketable securities, including the $15 million regulatory milestone payment earned in April 2022 upon European Commission approval of Kapruvia, will be sufficient to fund its currently anticipated operating expenses and capital requirements into the first half of 2024, without giving effect to any potential milestone payments under existing collaborations or product revenue from the commercialization of KORSUVA injection.

 

About Cara Therapeutics

 

Cara Therapeutics is an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s novel KORSUVA™ (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. Phase 2 proof-of-concept trials of Oral KORSUVA (difelikefalin) are ongoing in notalgia paresthetica and primary biliary cholangitis patients with moderate-to-severe pruritus. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.

 

Forward-looking Statements

 

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements include statements concerning the Company’s ability to successfully commercialize KORSUVA injection and Kapruvia, planned future regulatory submissions and potential future regulatory approvals, the Company’s ability to obtain and maintain coverage and adequate reimbursement for KORSUVA injection, the performance of the Company’s commercial partners, including Vifor Pharma, expected timing of the initiation, enrollment and data readouts from the Company’s planned and ongoing clinical trials, the potential results of ongoing clinical trials, timing of future regulatory and development milestones for the Company’s product candidates, the potential for the Company’s product candidates to be alternatives in the therapeutic areas investigated, the size and growth of the potential markets for pruritus management, the Company’s expected cash reach, and the potential impact of COVID-19 on the Company’s clinical development and regulatory timelines and plans. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Cara Therapeutics’ filings with the Securities and Exchange Commission, including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ending December 31, 2021 and its other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Cara Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

 

Financial tables follow

 

5

 

 

CARA THERAPEUTICS, INC.
CONDENSED BALANCE SHEETS
(in thousands)
(unaudited)

 

   March 31,   December 31, 
   2022   2021 
Assets          
Current assets:          
Cash and cash equivalents  $21,362   $13,453 
Marketable securities   119,749    153,582 
Accounts receivable - related party   2,496    - 
Inventory, net   1,907    2,584 
Income tax receivable   697    697 
Other receivables   438    455 
Prepaid expenses   5,113    2,519 
Total current assets   151,762    173,290 
Operating lease right-of-use assets   2,629    2,973 
Marketable securities, non-current   68,456    69,754 
Property and equipment, net   611    631 
Restricted cash   408    408 
Total assets  $223,866    247,056 
           
Liabilities and stockholders’ equity          
Current liabilities:          
Accounts payable and accrued expenses  $16,501   $15,861 
Operating lease liabilities, current   1,795    1,755 
Total current liabilities   18,296    17,616 
           
Operating lease liabilities, non-current   1,455    1,918 
           
Commitments and contingencies   -    - 
           
Stockholders' equity:          
Preferred stock   -    - 
Common stock   53    53 
Additional paid-in capital   714,292    708,585 
Accumulated deficit   (508,507)   (480,758)
Accumulated other comprehensive loss   (1,723)   (358)
Total stockholders’ equity   204,115    227,522 
Total liabilities and stockholders’ equity  $223,866   $247,056 

 

6

 

 

CARA THERAPEUTICS, INC.
CONDENSED STATEMENTS OF OPERATIONS
(amounts in thousands, except share and per share data)
(unaudited)

 

    Three Months Ended March 31, 
    2022   2021 
Revenue:           
Commercial supply revenue  $4,790   $- 
License and milestone fees   -    1,192 
Collaborative revenue   -    706 
Clinical compound revenue   -    37 
Total revenue    4,790    1,935 
            
Operating expenses:           
Cost of goods sold   2,081    - 
Research and development   21,273    19,131 
General and administrative   9,347    6,365 
Total operating expenses    32,701    25,496 
Operating loss    (27,911)   (23,561)
            
Other income, net    162    260 
Net loss   $(27,749)  $(23,301)
            
Net loss per share:           
Basic and diluted   $(0.52)  $(0.47)
            
Weighted average shares:           
Basic and diluted    53,507,060    49,917,990 

 

MEDIA CONTACT:

 

Annie Spinetta

6 Degrees

973-768-2170

aspinetta@6degreespr.com

 

INVESTOR CONTACT: 

 

Iris Francesconi, Ph.D. 

Cara Therapeutics 

203-406-3700 

investor@caratherapeutics.com

 

7

 

 EX-101.SCH 3 cara-20220509.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 cara-20220509_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 cara-20220509_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2214843d1_ex99-1img001.jpg GRAPHIC begin 644 tm2214843d1_ex99-1img001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBL34]2 MO9"UOI,!E?E7F'1#Z#MFIE)15V:4Z;J2LO\ @&O-/#;KNFE2-?5V JM_;&F_ M\_UO_P!_!7%3>']9N7,DH\R0^LJD_P ZH76C:A9J6FM9%4=6 R/S% H2T]K=^5CT^.1)4#QNKJ>A4Y%.KRBUOKFQE$D$KHP/0'@_45Z!H.N)J M\#!@$N$^\@Z$>HJZ6(4W9Z,PQ67SH+F3NC7HHHKH//"BN2UGXA:1I;M# 3>3 M*<$1G"C_ (%_AFL)/BN2XWZ0 GT;QIH^M%(XY M_)N&.!#+P2?8]#70U2:>Q2:>P445A>)/%-IX:C@-Q&\KS$[40C.!W_6AM)78 M-I*[-VBN<\-^,;/Q)<300PR0R1*'PY'S#..,?A^=='0FFKH$TU=!117'ZS\0 M;+1M6GT^6SGD>$@%E(P<@'^M#DH[@Y);G845P/\ PM33O^@?<_\ ?2U+;_%' M29)0LUM-;'P[>):RQ23S,NYEC(^0=LYI-I*[$VEJSIJ*PO#GBBU\203O;1 MO')"0&C.&2PG1I&"@@AAGS"G)_ GZ"ES*UPYEN;]%%%4 M,K:C?PZ9I\][<$B*%"S8ZGV'N:\7UCQGJVJ3NL,[VMKT2"$[0![D=37=?%"6 M5/#L"(2(Y+@!\=\ D#\_Y5YIX>BCF\1:=', 8VN$# ]"-PXKFJR?-RHPJR=^ M5'HW@_P:J6L>I:H\LEQ, Z1[V78#Z^IKN@BA-F/EQC!YXIU%;QBHJR-HQ45H M-KBP18Y5!+1CHWT]#65X0@G_ +99E!5$0B3/\OS_ )5WM,2*.,L4 M15+'+_$9F/C"<'H(T ^FT555M1T/-JNT="/PKX,N?$>ZX>7R+-#M,A7) M8^@']:[IOAGH1@V*UTK_ -_S!_+%:G@N.*/PAIPBQ@QECCU).?UK>HA3CRZB MA3C;4\FN?AKJ-MJMM':W DMY'YG P8L#SD]3^6:\W\!:=!=ZX;V\=$MK)1*S.<+NSA-?$"WLO[;%_8W<$R70R MZQ.&*L, YQZ\?K7<_#S5O[1\-K!))NFM&\LY/.WJO^'X44G:3B*F[-Q.MKP[ MQW_R.FH?[R?^@+7N->'>._\ D=-0_P!Y/_0%IU_A*K?"=;IWPVTV\TRTN7N[ M@--"DA P"0#577?AM;V.E7%Y:7KDP1F0I(H^8#D\BK>J>,KKPW8Z/;06\4J MR6$4A+DY!QC^E<[J_P 0]4U2QELQ%#!'*I5R@))![9-1+V:5K:D/V:5A/AWJ M<]GXEBM%<^1=95T[9 )!^O\ C7LU>3_#GP]PS M_*O6*THWY=2Z5^74CGGCMK>2>5@L<:EV8]@.37@VI7%QXD\2S2PHS27,N(TZ MD#H!^ Q7I?Q(U8V'AX6D9Q)>-LZ]%')_H/QKF/AO;6T%U!=9_L;Q'&DN?)N<0N/0D\'\#_6O:]B_W1^5 M>'>,X;2W\332Z?-$\$N)5,3 A2>HX]P3^->K^$]7.M^'K>ZS#D5X7=V=YH^H&*XC>&X MA;(SZ@\$5]$5DZI8QSQ_O[6&[A'42H&*CV/6N/&35*'M&FTM[:V^6_W$2I<^ MVY4\*>)[?Q!IT>9%%[&H$T9XY]1[&NAKBHM*T&WF$L>CQI*#D?O'X_6M235Y MMFR(*B@8&!T%>=+B#!PC\3D_)/\ 6QK&G/J:][?1VD9R@JAI=]++=-'(= MP?D>QK)S),_)+,?6MW2[ VP,DH_>,, >@KS,-CL7F..A*G[L(_=;S[M_\-W- M'%1B:5>8?$_191=1:Q&,Q,HBD]F&<'\1_*O3ZBN+>&[@>"XB26)QAD<9!KZZ M<>96.><>96/,/ WC6VTNT_LO4B4A5BT4H4D#)Y!Q[]Z]!;Q%HRP><=3M1'_> M\P5Q&M?#!FF,NCSJ$//DS$\?0XK&7X:^("V"+<#U,O%8IU(JUC).<=+'5WGQ M+TR+4[>&V5Y;8L1/-M(P.VT=Z[2WN(KJWCN('#Q2*&1AW!KAM"^&EI:,L^JR M_:95((B3A/Q[FNWD1XK-TLTC5U0B)2,(#C@<=JTAS[R-(N)[@R/C*C.P?3G-"?#C5+G5E MNM1NH)$DFWS[7.Y@3DXXKTV-%BC6-%"HH"JHZ "HC!R;(5AE.(;L"$^S9^4_GQ^->SD!E*D9!&"# M7E]Y\,[\:E++87,"0>9NBW.0RCMV[4I4W%IQ%*GRM.)ZC7AWCO\ Y'34/]Y/ M_0%KVJS%R+.$7A0W 4"0I]TMW(K@?$G@'4M8\075_!/;K'*5*AF(/"@>GM5U M4Y1T*JIN.AT-KX_M1-(EG&BG>PP-N>Q]Z\M\4Z!+XA]Q7MFFVSV>EVEM(07AA2-B.F0 *S_ !/X?A\0Z2]NRJ+A?F@D/\+? MX&B=.\=-PG"ZTW(?"'B&/Q!HZN1MN8 $F4# SC@CV-=!7G/A[P5K^@:K%=PW M5L8\XEC#MAU[CI7=:K%=3Z72&*3>RJQ))'(ZCUQ7I59PIMW6 M^2!G&<8K5^&6KM;ZO)ICM^YN5+*/]L#_ S^0KU2YMTNK66WE&8Y4*,/8C%> M8VGPXUJQOHKJ"ZM0\+AU.]AR#]*3IN$DXB<'&2<3U.BD&<#/7O170;BT444 M5I[&WGY9 #ZK4']CVWO^0K0HKBJY;@ZLN:=--^G^5BE)KJ00VD%N/W:#/J>M M3T45TTZ4*4>6FDEY$MW"F2RQP1F2618T'5F. *?4%Y9V]_;-;W42RPM@E&Z' M!R*T 2*^M)Y-D-U#(_7:C@FG?:[<0F;SXO*!P7WC /UKEO!.E6,<5Y=I;(L\ M=[/$CCJJ@XQ7'3S:L/ UY&MM!_9OVHYFW_/GS!V^M.P'K4UW;6^WS[B*/=R- M[@9I#>6JP"=Y/FIYN,[- MPW8]<5Q?@M#_ &[J\JVJ:=%&J1O9"3<5;^^?P%G-%A'JTUW;VQ GGBB+=-[@9_.E>X@CA\YYHUB/\98 ?G7&^+D M$WB/20--_M(&"4B#=MS]WG-9VI:?=Z=\.I8KN$1,]X'CMR^X1(6&$SZ?XT6& M>A0WEM36--<0R^"?#<,)]&TZ76](E>TC9[J[VS,<_. AX/Y#\J36X M(K7Q9X4@@01Q1F554= ,+Q18#J[B\MK10US<10@]#(X7/YT\2QM%YH=3'C.X M'C'KFN+L[>QU7Q)K"^(!&]Q#+LMHIWP%AYP5&>_4FKUY:Z.W@Z_L[#4HX+,L M4,IE+I&Q(^7.>!VQ[T6 Z.WN[:[4M;SQ2A3@F-PV/RJ:N(\*F&RU^2R?3[>W MN7M@RRVDY>.50>NW)P>>]=O28!1110 4444 %%%% !1110 4444 %%%% $%K M9V]DCI;1+&KN9& [L>IJL=#TTZ>]@;1/LKMO:+G!.TKY7;!JW10!573K19K>40+YENGEQ-DY5?3 M]*6^L+74K4VUY"LT)()1NF15FB@#/T[0]-TEW:PM$@:0 ,5)Y'XU%;>&M&M+ M[[;!I\*7& M>W),3GJF>N/RJS10!FZEH&E:O(LE_91S.HP&.0<>F14JZ3IZ:<=/6TB%H1@Q H;>#5VB@#-TW0-*TB1Y+"RCA=QAF!))'IR:TJ** "BBB@ HHHH __V0$! end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover
May 09, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 09, 2022
Entity File Number 001-36279
Entity Registrant Name CARA THERAPEUTICS, INC.
Entity Central Index Key 0001346830
Entity Tax Identification Number 75-3175693
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 4 Stamford Plaza
Entity Address, Address Line Two 107 Elm Street
Entity Address, Address Line Three 9th Floor
Entity Address, City or Town Stamford
Entity Address, State or Province CT
Entity Address, Postal Zip Code 06902
City Area Code 203
Local Phone Number 406-3700
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol CARA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 tm2214843d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001346830 2022-05-09 2022-05-09 iso4217:USD shares iso4217:USD shares 0001346830 false 8-K 2022-05-09 CARA THERAPEUTICS, INC. DE 001-36279 75-3175693 4 Stamford Plaza 107 Elm Street 9th Floor Stamford CT 06902 203 406-3700 false false false false Common Stock, par value $0.001 per share CARA NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://caratherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2214843d1_8k.htm cara-20220509.xsd cara-20220509_lab.xml cara-20220509_pre.xml tm2214843d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2214843d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm2214843d1_8k.htm" ] }, "labelLink": { "local": [ "cara-20220509_lab.xml" ] }, "presentationLink": { "local": [ "cara-20220509_pre.xml" ] }, "schema": { "local": [ "cara-20220509.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "CARA", "nsuri": "http://caratherapeutics.com/20220509", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2214843d1_8k.htm", "contextRef": "From2022-05-09to2022-05-09", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://caratherapeutics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2214843d1_8k.htm", "contextRef": "From2022-05-09to2022-05-09", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001104659-22-057509-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-057509-xbrl.zip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end